Conversely, in TP53-mutant NSCLC, the therapeutic benefit of XPO1 inhibition is diminished, as nuclear retention of mutant p53 may paradoxically support tumor progression by competing with other tumor suppressors and regulators. This evidence concerns the gene XPO1 and non-small cell lung carcinoma.